



2023

Annual Report





Introduction

Throughout 2023, the Global Alliance for Patient Access advanced patient-centered care by raising awareness and advocating for policies that ensure patient access.

GAfPA convened and facilitated discussions among health care stakeholders across a variety of conditions, including:

- **Cardiovascular disease**
- **Respiratory disease**
- **Chronic kidney disease**
- **Rheumatic disease**

Across the globe, GAfPA translated discussion into action.



Raising Awareness

In Australia, China, Canada and Europe, GAfPA led conversations on the importance of cholesterol screening and management, and the need for policies to promote access to novel immunizations for respiratory conditions.



Building Alliances

GAfPA spearheaded the creation of the Global Patient Alliance for Kidney Health, a group of more than 20 allied patient advocacy organizations from around the world, to advocate for greater access to screening and early treatment for chronic kidney disease.



Promoting Policy Advocacy

GAfPA developed and distributed multi-media advocacy resources to support patients and health care providers in their efforts to promote patient-centered care.

Digital Impact

Throughout the year, GAFPA spotlighted the benefits of **patient-centered care**. Metrics from 2023 reflect the commitment of advocates to raising awareness, improving policy and empowering patients to meet today's health care challenges.



6,596,218

ONLINE
IMPRESSIONS



48,193

SOCIAL MEDIA
FOLLOWERS



110,778

SOCIAL MEDIA
ENGAGEMENTS



150+

PARTICIPATING
ORGANIZATIONS



96,192

VIDEO VIEWS



18

MEETING
& EVENTS



Cardiovascular Disease

The leading cause of death globally, cardiovascular disease remained a focus of GAfPA's education and advocacy efforts in 2023.

High Cholesterol

In 2023, GAfPA launched an awareness campaign in Australia, *Know Your Numbers, Treat Your Risk*, to highlight the link between high LDL cholesterol and cardiovascular disease.

In China, GAfPA partnered with stakeholders to develop a campaign focused on the benefits of cholesterol management. And at the annual congress of the European Society of Cardiology, GAfPA convened patient advocates to assess how greater awareness might address unmet needs in managing atherosclerosis.

GAfPA also convened Canadian stakeholders to identify how to make LDL management a health priority in Canada.

These efforts build upon GAfPA's years of collaborating with stakeholders to identify country-specific unmet needs for patients living with high LDL cholesterol and the health care providers who diagnose and treat them.

Hypertension

Updates to treatment guidelines for hypertension in Europe spurred the European Alliance for Patient Access to undertake an education campaign about new treatment options and the need for awareness and access.

RESOURCES

Videos

- ▶ What's New in High Blood Pressure Management?
- ▶ Managing Your Cholesterol
- ▶ Rosemary Higgins
- ▶ Professor Charlotte Hespse

Reports

- ▶ Hypertension in Europe

One-pagers

- ▶ Cholesterol & Your Health
- ▶ Treatment Options: What you need to know
- ▶ The Cardiac Blues: What you need to know
- ▶ Talking with Your GP about Cholesterol

Blogs

- ▶ Calculating Cardiovascular Risk in Australia
- ▶ New European Hypertension Guidelines Pave the Way for Greater Access to High Blood Pressure Procedure
- ▶ Know Your Numbers, Treat Your Risk
- ▶ England Prioritizes Personalized Cardiovascular Care



Chronic Kidney Disease

Chronic kidney disease is a burdensome, prevalent condition that exacts a growing toll on patients, health care systems, the environment and governments worldwide.

GAfPA featured chronic kidney disease prominently in its advocacy efforts in 2023.

In March, GAfPA convened leading patient advocacy organizations from around the world to consider disease burden, the value of early screening and treatment, and how to improve access globally. The discussion ultimately led to the formation of the Global Patient Alliance for Kidney Health.

Composed of more than 20 patient advocacy organizations from four continents, the Global Patient Alliance for Kidney Health aims to enhance access to screening and early treatment of chronic kidney disease. The kidney health alliance launched on September 19, 2023, at Devex's "How Improving Kidney Health Can Transform Health Systems for All" event, which took place in New York City alongside the United Nations General Assembly meeting.

RESOURCES

Videos

- ▶ Chronic Kidney Disease: A Global Health Priority

Reports

- ▶ Chronic Kidney Disease: How Early Diagnosis Can Drive Better Outcomes

One-pagers

- ▶ Chronic Kidney Disease: A Global Challenge

Blogs

- ▶ New Kidney Health Alliance Elevates Chronic Kidney Disease on Global Health Agenda
- ▶ New Global Patient Alliance Is Raising Profile of Chronic Kidney Disease
- ▶ Why Chronic Kidney Disease Belongs on the WHO Agenda
- ▶ Early Detection Means Better Outcomes for Kidney Patients



Clinical Trials Awareness

Clinical trials can pave the way for patients to access innovative treatments, both now and in the future. But policies must encourage innovation so that clinical trials can open new doors and help patients achieve optimal health outcomes.

Promoting Innovation

Throughout 2023, GAFPA spotlighted global policies impacting innovation and their effect on clinical trials and patient access.

Efforts included:

- Creating advocacy resources to highlight the impact of policies on innovation and access to clinical trials
- Meeting with local stakeholders to identify local clinical trial needs and identify opportunities for education and advocacy
- Hosting a webinar on recent EU legislation that will impact clinical trials and innovation
- Crafting a bimonthly newsletter to highlight current trends in clinical trials policy

RESOURCES

▶ Videos

- ▶ Clinical Trials Access in Europe: Influence of Revisions to the EU Pharmaceutical Legislation
- ▶ Roundtable on the State of Clinical Trials in Brazil

📄 Papers

- ▶ The European Union's Revised Pharmaceutical Legislation: Impact on Patients & Medical Innovation

📝 Blogs

- ▶ Protecting Patient Access to Clinical Trials in Europe
- ▶ How EU Legislation Could Threaten Clinical Trials
- ▶ New Policy Shows Promise for Clinical Trials in Brazil



Respiratory Syncytial Virus

Respiratory syncytial virus, or RSV, places a heavy burden on babies and their families. Innovation has led to new immunizations that can protect many infants from the harm of this disease. But policies must ensure that all infants can access these treatments to receive the health benefits and to reduce the financial, social and emotional burdens experienced by families.

Understanding & Overcoming the Burden of RSV

In 2023, the Global Alliance for Patient Access worked with patient advocates and health care providers to better understand the barriers that RSV patients and their families face across the globe.

Efforts included:

- Convening stakeholders in China, Europe and Latin America to identify barriers to RSV immunizations that might be addressed through greater awareness and policy advocacy
- Highlighting the burden of RSV throughout China, Europe and Latin America
- Developing advocacy resources to raise awareness of RSV and advocate for policies to overcome barriers to care

RESOURCES

Papers

- ▶ The Burden of RSV: A Path to Awareness in Europe
- ▶ The Burden of RSV: A Path to Awareness in Latin America

Blogs

- ▶ The Power of Prevention



Rheumatic Disease

In 2023, GAFPA continued advocacy efforts related to rheumatic diseases - painful, sometimes debilitating conditions that impact millions globally.

Raising Awareness

With gout's global burden continuing to grow, GAFPA undertook an awareness campaign that culminated in the first ever Global Gout Awareness Day on May 22, 2023. The initiative brought together patients and other stakeholders to address stigma and lack of disease awareness - which have led to underdiagnosis and difficulties for patients managing their condition.

The campaign was accompanied by a suite of advocacy resources for various geographies, namely Australia, Europe and South Africa.

Convening Global Stakeholders

In December, GAFPA convened global stakeholders in rheumatic disease in Brussels for a meeting focused on the value of remission. The health care providers and patient advocates identified the benefits of remission and barriers to optimal care. Informed by these stakeholder perspectives, GAFPA will release a report in 2024 that summarizes their perspectives and sets forth an agenda of solutions to overcome the barriers to remission.

RESOURCES

Videos

- ▶ Gout Awareness Day

One-pagers

- ▶ Gout: A Growing Global Issue
- ▶ Getting Ahead of Gout - Australia
- ▶ Getting Ahead of Gout - Europe
- ▶ Getting Ahead of Gout - South Africa

Blogs

- ▶ Gout Awareness Day Gives Global Attention to a Global Disease



Moving Forward

In 2024, GAfPA will continue its advocacy and education on issues related to clinical trials, chronic kidney disease, cardiovascular health, rheumatic and respiratory diseases, and more.

GAfPA will also build upon its robust work related to chronic kidney disease to advance education, raise awareness and drive policy conversation to improve patient access to early screening and treatment.

This year offered advocates unique opportunities to engage patients and policymakers across the globe. GAfPA looks toward 2024 as a chance to strengthen partnerships, increase education and further the vision of patient-centered care for all people.



About the Global Alliance for Patient Access

The Global Alliance for Patient Access is an international platform for health care providers and patient advocates to inform policy dialogue about patient-centered care.

GAfPA.org

